American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
American Journal of Infectious Diseases and Microbiology. 2022, 10(2), 70-82
DOI: 10.12691/ajidm-10-2-3
Open AccessArticle

CD95 & CD178 Signaling Pathways and Associated Genetic Polymorphisms in the Patients with Chronic Viral Hepatitis B (VHB) Infection

Franklin Steve Azebaze Agueguia1, , Paul Talla2, Marie Claire Okomo Assoumou3, Cedric Happi Mbakam1, Elise Guiedem1, Martha Tongo Mesembe1, Emilia Lyonga1 and George Mondinde Ikomey1

1Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biological Sciences (FMBS), University of Yaoundé 1 (UY1), Cameroon

2Yaoundé General Hospital, Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences (FMBS), University of Yaoundé 1 (UY1), Cameroon

3Department of Microbiology, Hematology, Parasitology and Infectious Diseases, Faculty of Medicine and Biomedical Sciences (FMBS), University of Yaoundé 1 (UY1), Cameroon

Pub. Date: April 15, 2022

Cite this paper:
Franklin Steve Azebaze Agueguia, Paul Talla, Marie Claire Okomo Assoumou, Cedric Happi Mbakam, Elise Guiedem, Martha Tongo Mesembe, Emilia Lyonga and George Mondinde Ikomey. CD95 & CD178 Signaling Pathways and Associated Genetic Polymorphisms in the Patients with Chronic Viral Hepatitis B (VHB) Infection. American Journal of Infectious Diseases and Microbiology. 2022; 10(2):70-82. doi: 10.12691/ajidm-10-2-3


In Chronic Viral Hepatitis B (VHB), the mechanisms of the CD95-CD178 signaling pathway, and the associated genetic polymorphism, together with the cirrhotic process remains unclear. We evaluate the involvement of CD95-CD178 and associated genetic polymorphisms in viral persistence and hepatic cytolysis in patients with chronic VHB. Whole blood from 343 Chronic VHB patients were collected and, CD95 and CD178 levels were performed by Flow cytometry and ELISA, respectively. Genotyping of CD95-670 A/G, CD95-1377 G/A and CD178-844 C/T polymorphisms was performed using PCR-RFLP. The searches and quantifications of the DNA of the HBV were carried out by qPCR. Data were analyzed using GraphPad PRISM 7.0, with the significance threshold set at p ≤ 0.05 and a 95% confidence interval. Out of 343 patients, 105 (30.61%) were healthy and 238 (69.39%) were HBV-infected. Plasma levels of CD95 and CD178 were significantly elevated in HBV-infected patients compared to healthy patients, and in cirrhotic patients compared to non-cirrhotic patients. There were statistically significant correlations between CD95 and fibrosis scores, between CD95 and HBV viral load, between CD178 and fibrosis scores, between CD178 and HBV viral load, and between HBV viral load and the fibrosis score. The genotypic frequencies of CD95-670 A/G and CD178-844 C/T were significantly different between infected and healthy patients. Increased expression of CD95-670 A/G AG genotypes, CD95-1377 G/A GG genotypes, and CD178-844 C/T CT genotypes are associated with the severity of hepatic fibrosis, overexpression of CD95 and CD178 in patients infected with HBV, and by implication, the increase and persistence of the viral load of the Hepatitis B virus (HBV).

VHB CD95-CD178 genetic polymorphism HVB viral load fibrosis cirrhosis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Dane, D.S., Cameron, C.H. and Briggs, M, “Virus-like particles in serum of patients with Australia-antigen-associated hepatitis,” Lancet, vol. 1, no. 7649, pp. 695-698, 1970.
[2]  Alkahtani, S, “Hepatitis C infection and apoptosis in hepatocellular carcinoma,” Pak J Biol Sci, vol. 12, pp. 804-808, 2009.
[3]  Azebaze, A.F.S., Talla, P., Okomo, A.M.C., Jacobs, G., Mbakam, C.H., Guiedem, E., Mesembe, M.T., Lyonga, E. and George, M.I, “Involvement of CD95 and ligand in CD4+ T-cell and CD8+ T-cell depletion and hepatic cytolysis in patients with chronic viral hepatitis B,” African Journal of Laboratory Medicine, vol. 10, p. 6, 15 March 2021.
[4]  Maryam, K., Seyed, M. and Heidar, S, “Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients,” Jundishapur Journal of Microbiology, vol. 8, no. 3, p. e21444, 2015.
[5]  Zeisel, M.B., Fofana, I., Fafi-Kremer S. and al., “Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies,” J Hepatol, vol. 54, p. 566-76, 2011.
[6]  Pizon, M., Rampanarivo, H., Rampanarivo, S., Chaigne-Delalande, B., Daburon, S., Castroviejo, M., Moreau, P., Moreau, J.F. and Legembre, P, “Actin-independent exclusion of CD95 by PI3K/AKT signalling: implications for apoptosis,” The Journal of Immunology, vol. 41, no. 8, pp. 2368-2378, 2011.
[7]  Behrmann, I., Walczak, H. and Krammer, P.H, “Structure of the human APO-1 gene,” Eur J Immunol, vol. 24, no. 12, p. 3057-3062, 1994.
[8]  Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T. and Nagata, S, “Human Fas ligand: gene structure, chromosomal location and species specificity,” Int Immunol, vol. 6, no. 10, p. 1567-1574, 1994.
[9]  Huang, D.C., Hahne, M., Schroeter, M., Frei, K., Fontana, A., Villunger, A., Newton, K., Tschopp, J. and Strasser, A, “Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L),” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, p. 14871-14876, 1999.
[10]  Wu, J., Metz, C., Xu, X., Abe, R., Gibson, A.W., Edberg, J.C. and al., “A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients,” J Immunol, vol. 70, no. 1, pp. 132-138, 2003.
[11]  Lee, J.Y., Chae, D.W., Kim, S.M., Nam, E.S., Jang, M.K., Lee, J.H., Lee, H.Y. and Yoo, J.Y, “Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection,” Journal of Viral Hepatitis, vol. 11, p. 130-135, 2004.
[12]  Bortolami, M., Kotsafti, A., Cardin, R. and Farinati, F, “Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease,” J Viral Hepat, vol. 15, no. 7, p. 515-522, 2008.
[13]  Guicciardi, M.E. and Gores, G.J, “Apoptosis: a mechanism of acute and chronic liver injury,” Gut, vol. 54, no. 7, p. 1024-1033, 2005.
[14]  Miller, S.A., Dykes, D.D. and Polesky, H. F, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Res, vol. 13, no. 3, p. 1215, 1988.
[15]  Sun, T., Miao, X., Zhang, X., Tan, W., Xiong, P. and Lin, D, “Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma,” J Natl Cancer Inst, vol. 96, no. 3, p. 1030-1036, 2004.
[16]  Mann, B.H. and Withney, R.D, “On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other,” The Annals of Mathematical Statistics, vol. 18, n° %11, pp. 50-60, March 1947.
[17]  William, H.K. and Wallis, A.W, “Use of Ranks in One-Criterion Variance Analysis,” Journal of the American Statistical Association, vol. 47, n° %1260, pp. 583-621, 1952.
[18]  Peter, R.G., Walter, J.H., Henning, W., Heinz, S., Gerd, O., Wolfgang, S., Peter, H.K. and Laura, R, “Involvement of the CD95 (APO-1/Fas) Receptor and Ligand in Liver Damage,” Journal of Experimental Medicine, vol. 182, pp. 1223-1230, November 1995.
[19]  Leithäiuse, F., Dhein, J., Mechtersheimer, G., Koretz, K., Briiderlein, S., Henne, C., Schmidt, A., Debatin, K.M., Krammer, P.H. and Möller, P, “Constitutive and induced expression of APO-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells,” Laboratory Investigation, vol. 69, pp. 415-429, 1993.
[20]  Arakaki, R., Yamada, A., Kudo, Y., Hayashi, Y. and Ishimaru, N, “Mechanism of activation-induced cell death of T cells and regulation of FasL expression,” Critical Reviews in Immunology, vol. 34, p. 301-314, 2014.
[21]  Nagata, S, “Fas ligand-induced apoptosis,” Annual Review of Genetics, vol. 33, p. 29-55, 1999.
[22]  O'Connell, J., Bennett, M., O'Sullivan, G.C., Collins, J.K. and Shanahan, F, “The Fas counterattack: cancer as a site of immune privilege,” Immunology Today, vol. 20, pp. 46-52, 1999b.
[23]  Wilson, N.S., Dixit, V. and Ashkenazi, A, “Death receptor signal transducers: nodes of coordination in immune signaling networks,” Nature Immunology, vol. 10, p. 348-355, 2009.
[24]  Wagner, K.W., Punnoose, E.A., Januario, T., Lawrence, D.A., Pitti, R.M., Lancaster, K., Lee, D., Von Goetz, M., Yee, S.F., Totpal, K., Huw, L., Katta, V., Cavet, G., Hymowitz, S.G., Amler, L. and Ashkenazi, A, “Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL,” Nature Medicine, vol. 13, p. 1070-1077, 2007.
[25]  Liu, W., Lin, Y.T., Yan, X.L., Ding, Y.L., Wu, Y.L., Chen, W.N. and Lin, X, “Hepatitis B virus core protein inhibits Fas-mediated apoptosis of hepatoma cells via regulation of mFas/FasL and sFas expression,” FASEB J, vol. 29, no. 3, pp. 1113-1123, 2015.
[26]  Mueller, D.L, “Mechanisms maintaining peripheral tolerance,” Nature Immunology, vol. 11, p. 21-27, 2010.
[27]  Hayashi, N. and Mita, E, “Fas system and apoptosis in viral hepatitis,” Journal of Gastroenterology and Hepatology, vol. 12, no. 9-10, pp. S223-S226, 1997.
[28]  Chen, C.J., Yang, H., Su, J., Jen, C.L., You, S.L., Lu, S.N., Huang, G.T. and Iloeje, U.H, “Risk of hepato-cellular carcinoma across a biological gradient of serum hepatitis B virus DNA level,” Journal of the American Medical Association, vol. 295, pp. 65-73, 2006.
[29]  Liao, G.S., Lo, C.H., Chen, T.W. and al., “Fas/FasL polymorphisms are associated with hepatitis C related cirrhosis and serum Alpha-Fetoprotein with hepatocellular carcinoma patients,” J Cancer Res Prac, 2016.
[30]  Jung, Y.J., Kim, Y.J., Kim, L.H. and al., “Association présumée de polymorphismes des gènes Fas et FasL avec les résultats cliniques de l'infection par le virus de l'hépatite B,” Intervirologie, vol. 50, pp. 369-376, 2007.
[31]  Asadollah, M., Nader, T., Alireza, S.-H., Seyed, M.A., Zohreh, S. and Lida, J, “FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection,” Hepat Mon, vol. 15, no. 10, p. e26490, October 2015.
[32]  Agarwal, K, Czaja, A.J. and Donaldson, P.T, “A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis,” Tissue Antigens, vol. 69, no. 3, p. 227-235, 2007.
[33]  Marin, M., Muro, M., Moya-Quiles, M., Miras, M. Minguela, M., Bermejo and al., “Étude des polymorphismes de Fas (CD95) et de FasL (CD178) chez des greffés du foie,” Tissu Antigens, vol. 67, no. 2, p. 117-126, 2006.
[34]  Aguilar-Reina, J., Ruiz-Ferrer, M., Pizarro, M.A. and Antinolo, G, “Le polymorphisme -670A> G dans la région promotrice du gène FAS est associé à une nécrose des zones périortales chez les patients atteints d'hépatite chronique C,” J Hépat viral, vol. 12, no. 6, p. 568-573, 2005.
[35]  Zamani, A.G., Barlas, I.O., Durakbasi-Dursun, G., Oural, O., Erdal, E. and Yildirim, M.S, “Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection,” Int J Immunogenet, vol. 40, no. 6, p. 482-487, 2013.
[36]  McIlroy, D., Thodorou, I., Ratziu, V. and al., “FAS promoter polymorphisms correlatewith activity grade in hepatitis C patients,” Eur J Gastroenterol Hepatol, p. 1081-1088, 2005.